期刊文献+

文拉法辛与帕罗西汀治疗广泛性焦虑的对照研究 被引量:6

Control study of venlafaxine versus paroxetine in the treatment of generalized anxiety disorder
下载PDF
导出
摘要 目的比较文拉法辛与帕罗西汀治疗广泛性焦虑的疗效、功能改善及安全性。方法将68例广泛性焦虑患者随机分为2组,观察组服用文拉法辛,对照组服用帕罗西汀片,疗程6周。于治疗前及治疗后第1、2、4、6周末进行汉密尔顿焦虑量表(HAMA)、功能大体评定量表(GAF)及副反应量表(TESS)评定。结果两组患者HAMA总分、精神焦虑评分、躯体焦虑评分均呈下降趋势,观察组治疗第1周后的总分、精神焦虑因子分及治疗第2周后的躯体焦虑因子分各时点与治疗前比较差异均有统计学意义(P<0.05),对照组治疗第2周后的总分、精神焦虑因子分及治疗第4周后的躯体焦虑因子分各时点与治疗前比较差异均有统计学意义(P<0.05),但两组间主效应比较差异无统计学意义(P>0.05),观察组下降幅度较对照组下降幅度大,差异具有统计学意义(P<0.05)。两组患者GAF评分均呈不断升高趋势,治疗1周后各时点与治疗前比较差异均有统计学意义(P<0.05),但两组间主效应比较差异无统计学意义(P>0.05),两组间上升幅度比较差异无统计学意义(P>0.05);两组合并使用苯二氮卓类药物率差异无统计学意义(P>0.05);两组不良反应差异无统计学意义(P>0.05)。结论文拉法辛与帕罗西汀治疗广泛性焦虑安全、有效,能够较好改善社会功能,文拉法辛起效较快,改善躯体症状较好。 Objective To compare the effect , social function and safety of venlafaxine versus paroxetine in the treatment of general anxiety disorder .Methods Sixtyeight patients with generalized anxiety disorder were ran-domly divided into two groups .The observation group was given venlafaxine , the control group was given paroxetine for 6 weeks.The Hamilton Anxiety Scale(HAMA),global assessment function(GAF) and side effects scale(TESS) were used to assess the therapeutic effects before treatment and at the end of the 1st,2nd,4th,6th week after treatment, respectively.Results There was declined trend in HAMA′s total scores, mental anxiety scores and somatic anxiety scores in two groups .The MAMA′s total scores, mental anxiety scores at every time points after 1st week′s treatment and the HAMA′s somatic anxiety somatic anxiety scores at every time points after 2nd week′s treatment were significantly decreased in the observation group compared with those before treatment ( P〈0.05 ) .The HAMA′s total scores, mental anxiety scores at every time points after 2nd week′s treatment, the HAMA′s somatic anxiety scores at every time points after 4th week′s treatment were significantly decreased in the control group compared with those be-fore treatment ( P〈0.05 ) .There was no statistically difference in the main effect of HAMA′s scores between two groups(P 〉0.05).The declined amplitude in HAMA scores in the observation group was significantly greater than that in the control group ( P〈0.05 ) .There was an ascended trend in GAF′s scores in two groups .The GAF′s scores at every time points after 1st week′s treatment were significantly increased compared with those before treatment (P〉0.05 ) ,but there were no statistically difference in the main effect of GAF′s scores and the ascended amplitude in GAF′s scores between two groups ( P〉0.05 ) .There were no statistically difference in the rate of adverse reaction and the use of diazepams ( P〉0.05 ) .Conclusion Using venlafaxine and paroxetine for treating generalized anxiety disorder are effective and safe , but venlafaxine acts more rapidly and more improves the somatic symptoms compared with paroxetine .
出处 《中国临床新医学》 2014年第7期587-590,共4页 CHINESE JOURNAL OF NEW CLINICAL MEDICINE
基金 广西卫生厅科研课题(编号:Z2009161)
关键词 文拉法辛 帕罗西汀 广泛性焦虑 Venlafaxine Paroxetine Generalized anxiety disorder ( GAD)
  • 相关文献

参考文献8

  • 1中华医学会精神科分会.中国精神障碍分类与诊断标准[M].济南:山东科学技术出版社,2001.75-90.
  • 2中华神经精神科学会.中国精神疾病分类与诊断标准[M].南京:东南大学出版社,2006:74-86.
  • 3朱洪,刘亚峰.抗广泛性焦虑障碍药物的研究进展[J].华西医学,2008,23(5). 被引量:7
  • 4陆峥,张明园,蔡军,施慎逊,吴文源,季建林,张海音,刘义兰,周天骍,陈银娣,陈圣祺,赵宝龙,瞿正万,何燕玲.帕罗西汀治疗社交焦虑症的多中心开放性临床验证[J].中华精神科杂志,2002,35(2):115-118. 被引量:35
  • 5Connor KM, Davidson JR. Generalized anxiety disorder: neurobiologi- cal and phannacotherapeutic perspectives [ J ]. Biol Psychiatry, 1998, 44(12) :1286 - 1294.
  • 6Andrews JM, Ninan PT, Nemereff CB. Venlafaxine: a novel antide- pressant that has a dual mechanism of action [ J]. Depression, 1996, 4(2) :48 - 53.
  • 7Mcleod DR, Hoehn-Sarie R,Stefan RL. Somatic symptoms of anxiety: Comparison of self-report and physiological measures [ J ]. Biol Psy- chiatry,1986, 21 (3) :301 -310.
  • 8司天梅,舒良.文拉法辛对血压的影响(综述)[J].中国心理卫生杂志,2006,20(5):343-344. 被引量:10

二级参考文献24

  • 1赵靖平,瞿金国.广泛性焦虑障碍药物治疗进展[J].中国处方药,2004,3(7):50-53. 被引量:8
  • 2潘集阳.社会焦虑障碍的药物治疗[J].中国处方药,2004,3(7):54-55. 被引量:6
  • 3张石革,李鸿培,傅晓华,冯锋,卜力.神经精神系统合理用药专家圆桌会纪要[J].中国医院用药评价与分析,2005,5(2):67-70. 被引量:4
  • 4王燕.抗抑郁药的研究进展与应用评价[J].中国医院用药评价与分析,2005,5(2):81-84. 被引量:36
  • 5张明园.副反应量表[J].上海精神医学,1984,2:77-80.
  • 6Gutierrez MA, Stimmel GL, Aiso JY.Venlafaxine: a 2003 update. Clin Ther, 2003, 25:2138-2154.
  • 7Staid SM. Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects.J Clin Psychiatry, 1998, 59 (Suppl18) : 23 -29.
  • 8Van Londen L, Molenaar RP, Goekoop JG, et al. Three- to 5 - year prospective follow - up of outcome in major depression. Psychol Med,1998, 28:731 -735.
  • 9Feighner JP. Cardiovascular safety in depressed patients: focus on venlafaxine. J Clin Psychiatry. 1995,56 : 574- 579.
  • 10Thase ME. Effects of venlafaxine on blood pressure, a Meta - analysis of original data from 3744 depressed patients. J Clin Psychiatry. 1998, 59(10) : 502 -508.

共引文献345

同被引文献53

引证文献6

二级引证文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部